CA
NZ
UK
AU
IND
US
Growth during the quarter was supported by increased enterprise deal traction, FedRAMP authorization enabling broader government and regulated sector adoption, and the initial commercial rollout of the company's Embedded solution. FedRAMP authorization in particular opens the door to government and other highly regulated customers …
Biomarker and imaging data from the trial indicated that neflamapimod engaged its intended target, even though the overall cognitive endpoint was not achieved, which the company views as supportive of the drug's underlying mechanism. Safety data showed a discontinuation rate due to adverse events …
The company said these results reinforce the recommended Phase 2 dose selection and support planned expansion cohorts that will enroll additional patients. However, Coherus noted that the initial cohort size of 8 evaluable subjects is limited, meaning extended follow-up and confirmation in larger patient …
DBV ended the period with $165.7 million in cash, which the company said provides operational runway through the third quarter of 2027, giving it a multi-year window to advance the program without an immediate need for additional financing. The primary risk to the regulatory …
Management increased full year 2026 revenue guidance to a range of $775 million to $785 million, up from a prior range of $680 million to $700 million, reflecting confidence in the current pace of adoption. Looking further ahead, the company issued a preliminary 2027 …
Management raised full year 2026 guidance for BRINSUPRI to a range of $1.35 billion to $1.40 billion and for ARIKAYCE to $460 million to $470 million, reflecting confidence in sustainedDemandacross both products. The updated outlook was supported by BRINSUPRI's commercial entry into Japan, opening …
Iovance said data from the broader IOV-LUN-202 study is expected to support an anticipated submission of a supplementalBiologicsLicense Application in 2027. The company cautioned that the subgroup findings described above were identified retrospectively, meaning they were observed after the fact rather than defined before …
The company completed dosing in its 350-patient Phase 3 trial evaluating rexlemestrocel-L for chronic low back pain, with topline results expected in 2027. A positive readout could open a significant new indication for the cell therapy platform, given the large patient population affected by …
Management lifted full year 2026 revenue guidance to a range of $736 million to $743 million and raised adjusted EBITDA guidance to $24 million to $34 million, reflecting steady momentum across existing indications. The improved outlook followed Japanese regulatory authorization of Optune Pax for …
● No major company announcement accompanied the advance.
Please wait processing your request...